Singapore markets open in 1 hour 43 minutes

Clene Inc. (CLNN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3510+0.0027 (+0.78%)
At close: 04:00PM EDT
0.3575 +0.01 (+1.85%)
After hours: 07:35PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3483
Open0.3640
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.3400 - 0.3642
52-week range0.2500 - 1.0900
Volume273,660
Avg. volume842,820
Market cap45.08M
Beta (5Y monthly)0.47
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Clene to Present at Upcoming May Conferences

    SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, today announced that it will participate in the following investor conferences in May. Mizuho Neuroscienc

  • GlobeNewswire

    Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

    Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Peer-reviewed publication characterized the protein corona of CNM-Au8Company received sub-award of $7.3 million from NIH grant for ALS Expanded Access ProgramCash, cash equivalents and marketable securities of $27.9 million as of March 31, 2024 SALT LAKE CITY, May 08, 2024 (GLOB

  • GlobeNewswire

    IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington

    LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN), recently appeared on From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, ho